Abnormalities in T cell subsets in the circulating immunity and tumor microenvironment in patients with pancreatic ductal adenocarcinoma

doi:10.16139/j.1007-9610.2025.02.13

Abstract

Abstract:

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant solid tumor of digestive system, which can affect the immune system. The abnormalities of distribution, percentage, function, and activity of immune cells in both peripheral circulation and tumor microenvironment (TME) are detected in patients with PDAC. T cells are the main lymphocytes that participate in cell-mediated immunity and exert anti-tumor effects. According to the function and the cluster of differentiation, T cells can be divided into different subsets, such as CD4⁺, CD8⁺, CD4⁺ CD25⁺, etc. The abnormalities of T cell subsets in the circulating immunity and TME of patients with PDAC may play an important role in cancer progress.

Key words: Pancreatic ductal adenocarcinoma (PDAC), Circulating immunity, Tumor microenvironment (TME), T cell subset

CLC Number:

R735.9

SU Bingwei, SHEN Baiyong. Abnormalities in T cell subsets in the circulating immunity and tumor microenvironment in patients with pancreatic ductal adenocarcinoma[J]. Journal of Surgery Concepts & Practice, 2025, 30(2): 171-175.

References 44

[1]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
[2]	国家卫生健康委办公厅. 胰腺癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(5):1006-1015.
	General Office of the National Health Commission of China. Standard for diagnosis and treatment of pancreatic cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(5):1006-1015.
[3]	SIEGEL R L, GIAQUINTO A N, JEMAL A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1):12-49.
[4]	GORAL V. Pancreatic cancer: pathogenesis and diagnosis[J]. Asian Pac J Cancer Prev, 2015, 16(14):5619-5624.
[5]	BALACHANDRAN V P, ŁUKSZA M, ZHAO J N, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer[J]. Nature, 2017, 551(7681):512-516.
[6]	YING H, YAO W. The prospects of immunotherapy in pancreatic cancer[M]// Pancreat Cancer Multidiscip Approach. Cham:Springer,2022:269-281.
[7]	AJINA R, WEINER L M. T-Cell immunity in pancreatic cancer[J]. Pancreas, 2020, 49(8):1014-1023.
[8]	DALEY D, ZAMBIRINIS C P, SEIFERT L, et al. γδ T cells support pancreatic oncogenesis by restraining αβ T cell activation[J]. Cell, 2016, 166(6):1485-1499.e15. doi: S0092-8674(16)30996-5 pmid: 27569912
[9]	LAFONT V, SANCHEZ F, LAPREVOTTE E, et al. Plasticity of γδ T cells: impact on the anti-tumor response[J]. Front Immunol,2014, 5:622 doi: 10.3389/fimmu.2014.00622 pmid: 25538706
[10]	MCALLISTER F, BAILEY J M, ALSINA J, et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia[J]. Cancer cell, 2014, 25(5):621-637.
[11]	LI J, MORESCO P, FEARON D T. Intratumoral NKT cell accumulation promotes antitumor immunity in pancreatic cancer[J]. Proc Natl Acad Sci USA, 2024, 121(29):e2403917121.
[12]	JANAKIRAM N B, MOHAMMED A, BRYANT T, et al. Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras^G12D/+ mice[J]. Immunology, 2017, 152(1):36-51.
[13]	XU Y F, LU Y, CHENG H, et al. Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival[J]. Pancreatology, 2014, 14(4):295-301.
[14]	LIYANAGE U K, MOORE T T, JOO H G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma[J]. J Immunol, 2002, 169(5):2756-2761. doi: 10.4049/jimmunol.169.5.2756 pmid: 12193750
[15]	O'NEILL R E, CAO X. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy[J]. Adv Cancer Res, 2019,143:145-194.
[16]	LIU C, CHENG H, LUO G, et al. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer[J]. Int J Oncol, 2017, 51(2):686-694. doi: 10.3892/ijo.2017.4032 pmid: 28714519
[17]	YAMAMOTO T, YANAGIMOTO H, SATOI S, et al. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer[J]. Pancreas, 2012, 41(3):409-415.
[18]	STROMNES I M, HULBERT A, PIERCE R H, et al. T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma[J]. Cancer Immunol Res, 2017, 5(11):978-991. doi: 10.1158/2326-6066.CIR-16-0322 pmid: 29066497
[19]	BAILEY P, CHANG D K, NONES K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer[J]. Nature, 2016, 531(7592):47-52.
[20]	PENG J, SUN B F, CHEN C Y, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma[J]. Cell Res, 2019, 29(9):725-738. doi: 10.1038/s41422-019-0195-y pmid: 31273297
[21]	BALLI D, RECH A J, STANGER B Z, et al. Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer[J]. Clin Cancer Res, 2017, 23(12):3129-3138. doi: 10.1158/1078-0432.CCR-16-2128 pmid: 28007776
[22]	RYSCHICH E, NÖTZEL T, HINZ U, et al. Control of T-cell-mediated immune response by HLA class Ⅰ in human pancreatic carcinoma[J]. Clin Cancer Res, 2005, 11(2 Pt 1):498-504.
[23]	TANG Y, XU X, GUO S, et al. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma[J]. PLoS one, 2014, 9(3):e91551.
[24]	CARSTENS J L, CORREA DE SAMPAIO P, YANG D, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer[J]. Nat Commun,2017, 8:15095 doi: 10.1038/ncomms15095 pmid: 28447602
[25]	YOUSUF S, QIU M, VOITH VON VOITHENBERG L, et al. Spatially resolved multi-omics single-cell analyses inform mechanisms of immune dysfunction in pancreatic cancer[J]. Gastroenterology, 2023, 165(4):891-908.e14.
[26]	LIU W, PUTNAM A L, XU-YU Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells[J]. J Exp Med, 2006, 203(7):1701-1711. doi: 10.1084/jem.20060772 pmid: 16818678
[27]	SAHAI E, ASTSATUROV I, CUKIERMAN E. A framework for advancing our understanding of cancer-associa-ted fibroblasts[J]. Nat Rev Cancer, 2020, 20(3):174-186.
[28]	ÖHLUND D, HANDLY-SANTANA A, BIFFI G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer[J]. J Exp Med, 2017, 214(3):579-596.
[29]	JENKINS L, JUNGWIRTH U, AVGUSTINOVA A. Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade[J]. Cancer Res, 2022, 82(16):2904-2917.
[30]	TAN M C, GOEDEGEBUURE P S, BELT B A, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer[J]. J Immunol, 2009, 182(3):1746-1755. doi: 10.4049/jimmunol.182.3.1746 pmid: 19155524
[31]	PAN Y, LU F, FEI Q, et al. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancrea-tic cancer[J]. J Hematol Oncol, 2019, 27, 12(1):124.
[32]	POSCHKE I, FARYNA M, BERGMANN F, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma[J]. Oncoimmunology, 2016, 5(12):e1240859.
[33]	ZHANG Y, LAZARUS J, STEELE N G, et al. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis[J]. Cancer Discov, 2020, 10(3):422-439. doi: 10.1158/2159-8290.CD-19-0958 pmid: 31911451
[34]	DAS S, SHAPIRO B. Tumor cell-derived IL1β promotes desmoplasia and immune suppression in pancreatic cancer[J]. Cancer Res, 2020, 80(5):1088-1101. doi: 10.1158/0008-5472.CAN-19-2080 pmid: 31915130
[35]	LEINWAND J, MILLER G. Regulation and modulation of antitumor immunity in pancreatic cancer[J]. Nat Immunol, 2020, 21(10):1152-1159. doi: 10.1038/s41590-020-0761-y pmid: 32807942
[36]	FAN J Q, WANG M F, CHEN H L, et al. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma[J]. Mol Cancer, 2020, 19(1):32.
[37]	SHA H, TONG F, NI J, et al. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase Ⅱ trial[J]. Signal Transduct Target Ther, 2024, 9(1):143.
[38]	PARIKH A R, SZABOLCS A, ALLEN J N, et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase Ⅱ trial[J]. Nat Cancer, 2021, 2(11):1124-1135.
[39]	ZHANG H, XU W, ZHU H, et al. Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: combining radiotherapy and metabolic targeting therapy[J]. J Cancer, 2024, 15(7):2003-2023. doi: 10.7150/jca.92502 pmid: 38434964
[40]	PANT S, WAINBERG Z A, WEEKES C D, et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial[J]. Nat Med, 2024, 30(2):531-542. doi: 10.1038/s41591-023-02760-3 pmid: 38195752
[41]	ROJAS L A, SETHNA Z, SOARES K C, et al. Persona-lized RNA neoantigen vaccines stimulate T cells in pancreatic cancer[J]. Nature, 2023, 618(7963):144-150.
[42]	SETHNA Z, GUASP P, REICHE C, et al. RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer[J]. Nature, 2025, 639(8056):1042-1051.
[43]	LOPEZ J, POWLES T, BRAITEH F, et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial[J]. Nat Med, 2025, 31(1):152-164. doi: 10.1038/s41591-024-03334-7 pmid: 39762422
[44]	MUSHER B L, ROWINSKY E K, SMAGLO B G, et al. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study[J]. Lancet Oncol, 2024, 25(4):488-500. doi: 10.1016/S1470-2045(24)00079-2 pmid: 38547893